Get our latest issue now

available for iOS, Android & web

latest issue

Russia approves Novartis' oral MS drug Gilenya

Daily News | September 10, 2010

Kevin Grogan

Russia approves Novartis' oral MS drug Gilenya

Novartis has received approval for its once-daily oral multiple sclerosis drug Gilenya from Russia, the first country to give the pill the thumbs-up.

The Federal Service on Surveillance in Healthcare and Social Development, the Russian health authority, has given the green light to Gilenya (fingolimod) for relapsing-remitting MS. Novartis expects to launch Gilenya, the first in a new class of compounds called sphingosine 1-phosphate receptor modulators, in Russia in early 2011.

The approval comes two months after Russia backed Merck KGaA's rival oral MS drug Movectro (cladribine). However, Novartis is ahead in the USA, after the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee recommended approval of fingolimod, in June.

The FDA is expected to give its final decision this month  and Gilenya is also under review by the European Medicines Agency.

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!